Clinical trials: Depressions, Refractory
Treatment Resistant Depression (TRD)
Parcel-guided rTMS for Major Depressive Disorder
Study comparing standard repetitive transcranial magnetic stimulation (rTMS) for Depression to a novel targeting approach using brain surface parcellation to locate a specific brain target.
- Trial name
- NCT07287839
- Testing
- Accelerated rTMS, Parcel-guided Accelerated rTMS
- Volunteers
- 60 people
- Sponsor
- Soterix Medical
Major Depressive Disorder, Recurrent Depressive Disorder
Deep Brain Stimulation in Patients With Chronic Treatment Resistant Depression
Major depressive disorders are real public health issues in terms of diagnosis and treatment. Some forms of depression are chronic and resistant to treatment (TRD). In these forms suicide risk is important.
- Conditions
- Major Depressive Disorder, Recurrent Depressive Disorder, Bipolar Disorder
- Trial name
- STHYM (NCT01973478)
- Testing
- DBS
- Where
- 5 sites in France
- Volunteers
- 9 people
- Sponsor
- Rennes University Hospital
Multiple Sclerosis, Major Depressive Disorder
Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis
The goal of this single-arm, observational pilot study is to learn about the safety, feasibility, preliminary efficacy of TMS for the treatment of depression in people with MS.
- Conditions
- Multiple Sclerosis, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- NCT06329414
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Treatment Resistant Depression
Accelerated High-dose Sequential Bilateral Theta Burst Stimulation for Treatment Resistant Depression
Repetitive transcranial magnetic stimulation (rTMS) and Theta burst stimulation (TBS) are approved by the US. Food and Drug administration (FDA) for the treatment of refractory major depression.
- Trial name
- NCT05811104
- Testing
- Sequential bilateral theta burst stimulation
- Volunteers
- 40 people
- Sponsor
- University of Calgary
Treatment Resistant Depression, Depression
Glutamate Emotion Memory Study
Clinical depression often includes a pessimistic view of things which have happened in the past and an impairment in the ability to experience pleasure or looking forward to things.
- Conditions
- Treatment Resistant Depression, Depression, Major Depressive Disorder
- Trial name
- GEMS (NCT05809609)
- Testing
- Ketamine Hydrochloride
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Oxford
Subjects Had Unipolar, Non-psychotic Major Depression
Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression
Atypical neuroleptics may have antidepressant qualities in bipolar depression and in unipolar depression. Some data support the use of both Risperidone and Olanzapine, but there are no direct comparisons of their relative…
- Trial name
- NCT01282632
- Testing
- Risperidone, Olanzapine
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- Sunnybrook Health Sciences Centre
Treatment-Resistant Depression
Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychological support in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects.
- Trial name
- PSI-TNT (NCT07211438)
- Testing
- Psilocybin
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Centre for Addiction and Mental Health
Treatment Resistant Depression, Major Depressive Disorder
Predictors of Intravenous Ketamine Response in TRD
For patients with treatment-resistant depression (TRD), a single low dose of intravenous (IV) ketamine can help relieve symptoms as quickly as 24 hours later.
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Bipolar Disorder
- Trial name
- NCT05625555
- Testing
- Ketamine, Midazolam
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Abraham Nunes
Borderline Personality Disorder (BPD), Treatment-Resistant Major Depressive Disorder
Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)
The goal of this clinical trial is to learn if intravenous (IV) ketamine with Dialectical Behavioural Therapy (DBT) reduces suicidal ideation in individuals with suicidality who have been diagnosed with Borderline Personality…
- Conditions
- Borderline Personality Disorder (BPD), Treatment-Resistant Major Depressive Disorder, Treatment-resistant Bipolar Depression, Major Depressive Disorder (MDD)
- Trial name
- KET-DBT (NCT07569198)
- Testing
- Ketamine Hydrochloride, Midazolam Hydrochloride, Dialectical Behavioral Therapy (DBT)
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Joshua Rosenblat
Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder
The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression.
The goal of this clinical trial is to test whether a personalized approach to treatment selection improves symptoms in older adults with treatment-resistant depression.
- Conditions
- Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- BAARD (NCT07810738)
- Testing
- Aripiprazole Augmentation, Bupropion Augmentation
- Where
- 3 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Washington University School of Medicine
Depressive Disorder, Major
Deep Brain Stimulation for Treatment Resistant Depression
This study will investigate the safety and efficacy of deep brain stimulation (DBS) in lateral habenula (LH) for patients with treatment-resistant depression.
- Trial name
- NCT05716555
- Testing
- Deep brain stimulation
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Major Depressive Disorder
E-field Guided iTBS for Treatment Resistant Depression
The purpose of this study is to establish how personalization of repetitive transcranial magnetic stimulation (rTMS) can change markers of brain activity and improve treatment response.
- Trial name
- NCT05583747
- Testing
- iTBS
- Where
- 2 sites in Canada
- Volunteers
- 110 people
- Sponsor
- Centre for Addiction and Mental Health
Treatment Resistant Major Depressive Disorder
DBS of the Lateral Habenula in Treatment-Resistant Depression
This research study will investigate the safety, tolerability, and benefit of bilateral deep brain stimulation (DBS) to the lateral habenula in subjects with treatment-resistant major depression (TRD) secondary to either…
- Trial name
- NCT01798407
- Testing
- Activa Tremor Control Sys (DBS Implant), Randomized, staggered withdrawal phase
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Wayne Goodman MD
Depression
Fermented Milk Product With Probiotic and Its Impact on Mood of Patients With Treatment Resistant Depression
This study aims to assess the impact of a chronic dietary intervention (8 weeks) with probiotics, specifically Fermented Milk Product with Probiotic (FMPP), on the mood of individuals with Major Depressive Disorder (MDD)…
- Trial name
- NCT03317678
- Testing
- BioKefir, Non-fermented milk
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Rush University Medical Center
Major Depressive Disorder, Treatment Resistant Depression
Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression
This study tests whether a brain stimulation treatment for depression called intermittent theta burst stimulation (iTBS) can be improved by tailoring it to each individual.
- Trial name
- NCT07528157
- Testing
- Personalized iTBS, Non-Personalized iTBS
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Stanford University
Treatment Resistant Depression (TRD)
Comparison of Different Acceleration Modes of Transcranial Magnetic Stimulation
To compare the efficacy and safety of 6 times a day, 10 times a day acceleration mode and sham stimulation intervention for TRD, and to explore the antidepressant mechanism of accelerated mode, so as to provide a more simple and…
- Trial name
- NCT06881030
- Testing
- Noninvasive transcranial magnetic stimulation was administered six times daily, Noninvasive transcranial magnetic stimulation was administered 10 times daily
- Volunteers
- 45 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms)
Deep Phenotyping for Clinical Inferring Response in Treatment Resistant Depression
DECIDE- Deep phenotyping for clinical inferring response in treatment resistant depression -Study Building upon the "Biobanking" initiative at the Max Planck Institute of Psychiatry, the present project aims to identify…
- Conditions
- Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms), Depressive Disorder, Major, Recurrent, With Psychotic Symptoms, Depressive Disorder, Major, Recurrent, Without Psychotic Symptoms
- Trial name
- DECIDE (NCT06396312)
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Max-Planck-Institute of Psychiatry
Treatment Resistant Depression, Major Depressive Disorder (MDD)
Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression
The goal of this clinical trial is to see if combining ketamine with behavioral activation (BA) therapy to treat moderate to severe treatment-resistant depression improves depressive symptoms and general functioning more than…
- Trial name
- NCT07801703
- Testing
- Ketamine (0.5 mg/kg), Behavioural Activation Therapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- The Royal's Institute of Mental Health Research
Treatment Resistant Depression
A Study in Relapse Prevention of Treatment-Resistant Depression
The purpose of this study is to determine whether olanzapine and fluoxetine combination (OFC) if used for a long time (47 weeks) makes patients suffering from Treatment Resistant Depression stable, determine if OFC is safe when…
- Trial name
- NCT00958568
- Testing
- Olanzapine and Fluoxetine combination (OFC), Fluoxetine
- Where
- 66 sites in United States, Argentina and 6 more
- Volunteers
- 892 people
- Sponsor
- Eli Lilly and Company